United States: FDA Uses Summer To Issue Numerous Device Guidance Documents

Last Updated: September 6 2016
Article by M. Elizabeth Bierman and Michele Buenafe

The Agency shows no signs of slowing regulatory activity.

Although the US Food and Drug Administration's (FDA's or the Agency's) Center for Devices and Radiological Health (CDRH) has been very active throughout 2016, it appears to have stepped up its guidance development activity even more this summer. During June and July, CDRH issued 15 draft and final guidance documents addressing a wide variety of both premarket and postmarket issues, including general wellness devices, next-generation sequencing in vitro diagnostic devices, companion diagnostics, categorization of investigational device exemptions (IDEs) for reimbursement purposes, adaptive designs for clinical studies, and benefit-risk analyses affecting compliance and enforcement decisions.

To help update those clients and friends who may have not have kept up with CDRH's fast-paced issuance of guidance documents this summer, we have provided below brief summaries of draft and final guidance documents issued in the June to July 2016 time period.

General Wellness: Policy for Low Risk Devices

This Final Guidance, issued on July 29, establishes FDA's compliance policy for low-risk devices intended to promote a healthy lifestyle. FDA does not intend to actively regulate products that are both intended for general wellness purposes (e.g., weight management, physical fitness, and sleep management) and are low risk, as those criteria are defined in the Final Guidance. This means the products that meet these criteria will not be subject to any premarket submission requirements or to any other device regulatory requirements, including registration, listing, labeling, quality system, or reporting requirements. To read more about this Final Guidance document, see our LawFlash: FDA Issues Final Guidance For General Wellness Devices.

Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices

FDA issued this Draft Guidance on July 27 to recognize the valuable data on medical device experiences that are routinely collected from sources outside of traditional clinical trials. The Draft Guidance describes various circumstances under which real-world evidence may be used in different FDA contexts. These include to generate hypotheses to be tested in a prospective clinical study, as a historical control, for public health surveillance efforts, and for post-approval studies.

Adaptive Designs for Medical Device Clinical Studies

An adaptive design study is a clinical study design that allows for prospectively planned modifications based on accumulating study data without undermining a study's integrity and validity. This Final Guidance, which issued on July 27, addresses issues related to the use of adaptive designs in device clinical studies intended to support a marketing submission. Among these issues are when to choose an adaptive design, advantages and limitations of adaptive designs, how to control the chance of erroneous conclusions and minimize operational bias, various types of adaptive designs, and regulatory considerations.

Unique Device Identification System: Form and Content of the Unique Device Identifier

FDA issued yet another Draft Guidance on unique device identifiers (UDIs) on July 26 as it continues the march toward UDI implementation. The Draft Guidance sets forth a UDI's expected content and forms to ensure that UDIs comply with the UDI regulation at 21 C.F.R. § 801.40.

Principles for Codevelopment of an In Vitro Companion Diagnostic Device with a Therapeutic Product

An in vitro diagnostic (IVD) companion device is an IVD that provides information required for the safe and effective use of a corresponding therapeutic product. In most cases, FDA's market authorization for the two products should occur contemporaneously. The Draft Guidance, which issued on July 15, is intended to provide practical advice to assist both the sponsor of an IVD and the sponsor of a therapeutic product in the product development and review process. This includes advice relating to IVD validation requirements, therapeutic product clinical trial design issues, labeling, coordinating review timelines, and post-marketing considerations.

Information to Support a Claim of Electromagnetic Compatibility of Electrically-Powered Medical Devices

This Final Guidance, issued on July 11, describes the information that should be included in a premarket submission to support a claim of electromagnetic compatibility (EMC) for an electrically-powered medical device.

Use of Standards in FDA Regulatory Oversight of NGS-Based IVDs Used for Diagnosing Germline Diseases

As we discussed in our prior LawFlash, FDA Issues Draft Guidance As Part of Precision Medicine Initiative, this Draft Guidance document and the one below issued on July 8 to address next generation sequencing (NGS)–related issues that may affect both test developers and genetic database administrators. The above-titled Draft Guidance describes the use of standards and the FDA's de novo classification mechanism to develop a potential pathway to market for NGS-based tests for germline diseases.

Use of Public Human Genetic Variant Databases to Support Clinical Validity for NGS-Based IVDs

This Draft Guidance, which issued on July 8 along with the guidance discussed immediately above, describes how publicly accessible databases of human genetic variants can be a source of valid scientific evidence to support the validity of NGS-based tests.

Procedures for Evaluating Appearance Issues and Granting Authorization for Participation in FDA Advisory Committees

This Draft Guidance, issued on June 27, discusses FDA's process for evaluating whether an advisory committee member has interests or relationships that do not require recusal but present an appearance of a lack of impartiality.

Leveraging Existing Clinical Data for Extrapolation to Pediatric Uses of Medical Devices

This Final Guidance, issued on June 21, aims to increase the availability of safe and effective pediatric devices by clarifying the specific criteria that FDA applies in deciding whether leveraging existing clinical data to support pediatric claims is appropriate, and if so, to what extent. Understanding the challenges associated with conducting pediatric clinical trials, the Final Guidance describes and provides examples from a complex "decision tree" to aid in identifying the appropriate scope of extrapolations, associated benefits, and potential pitfalls to avoid or address.

Evaluation and Reporting of Age, Race, and Ethnicity Data in Medical Device Clinical Studies

This Draft Guidance document, issued on June 20, outlines the FDA's expectations and recommendations for the evaluation and reporting of age, race, and ethnicity data in medical device clinical studies that support a marketing submission. In issuing the Draft Guidance, FDA intends to encourage collection and consideration (during the study design stage) of relevant age, race, ethnicity, and associated covariates for devices for which safety, effectiveness, or benefit-risk profile is expected to vary across these groups.

Use of International Standard ISO 10993—Biological Evaluation of Medical Devices, Part 1

This Final Guidance, issued on June 16, addresses biocompatibility testing required for medical devices that are the subject of a premarket submission and come into direct or indirect contact with the human body. As of September 14, 2016, the Final Guidance will supersede the FDA's 1995 guidance on use of International Standard ISO 10993 for biocompatibility testing. The Final Guidance incorporates updates to ISO 10993 and describes use of risk-based approaches to determine if biocompatibility testing is needed.

Factors to Consider Regarding Benefit-Risk in Medical Device Product Availability, Compliance, and Enforcement Decisions

One of FDA's missions is to limit the availability of violative medical devices and to pursue compliance and enforcement actions related to violative products. FDA recognizes, however, that decisions regarding potential compliance and enforcement actions are fact-specific and should include consideration of the potential effect on patients. This Draft Guidance, issued on June 16, discusses the benefit and risk factors that FDA may consider in prioritizing the Agency's resources for compliance and enforcement efforts.

Dissemination of Patient-Specific Information from Devices

This Draft Guidance, issued on June 10, is intended to facilitate the appropriate and responsible dissemination of patient-specific information recorded, stored, processed, retrieved, and/or derived from medical devices from manufacturers to patients. In particular, the Draft Guidance is intended to clarify that FDA regulations and guidance do not prohibit device manufacturers from sharing such information with patients and that sharing this information with patients does not require additional premarket review. Refer to our LawFlash, FDA Clarifies Policy for Sharing Patient-Specific Data from Devices, for additional information on this guidance.

FDA Categorization of IDE Devices to Assist CMS with Coverage Decisions

This Draft Guidance, issued on June 1, is intended to provide information on the FDA's categorization of investigational devices, to help support coverage (i.e., reimbursement) decisions by the Centers for Medicare & Medicaid Services (CMS). Although certain devices with an approved IDE may be covered under Medicare, over the years, FDA has received a number of IDEs that do not fit into the previously established categorization framework. Therefore, CMS and FDA are revising their shared understanding regarding the categorization of IDE devices to help ensure that devices will not be precluded from reimbursement because of an inappropriate reimbursement categorization determination.

This article is provided as a general informational service and it should not be construed as imparting legal advice on any specific matter.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement

    Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of www.mondaq.com

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

    Disclaimer

    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

    Registration

    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

    Cookies

    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

    Links

    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

    Mail-A-Friend

    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

    Emails

    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

    Security

    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at enquiries@mondaq.com.

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions